See more : United Utilities Group PLC (UUGRY) Income Statement Analysis – Financial Results
Complete financial analysis of CalciMedica, Inc. (CALC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CalciMedica, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- M3, Inc. (MTHRY) Income Statement Analysis – Financial Results
- Global SPAC Partners Co. (GLSPU) Income Statement Analysis – Financial Results
- BCE Inc. (BECEF) Income Statement Analysis – Financial Results
- Automobile & PCB Inc. (015260.KS) Income Statement Analysis – Financial Results
- Sabre Insurance Group plc (SBIGY) Income Statement Analysis – Financial Results
CalciMedica, Inc. (CALC)
About CalciMedica, Inc.
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 58.00K | 52.00K | 519.00K | 395.00K | 303.00K | 175.00K |
| Gross Profit | -58.00K | -52.00K | -519.00K | -395.00K | -303.00K | -175.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 12.36M | 14.11M | 18.90M | 20.96M | 30.58M | 22.97M |
| General & Administrative | 0.00 | 19.10M | 17.04M | 8.87M | 6.92M | 5.60M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.46M | 19.10M | 17.04M | 8.87M | 6.92M | 5.60M |
| Other Expenses | 0.00 | 2.96M | 0.00 | 2.16M | 72.00K | 0.00 |
| Operating Expenses | 21.82M | 33.22M | 35.95M | 29.83M | 37.50M | 28.57M |
| Cost & Expenses | 21.88M | 33.22M | 35.95M | 29.83M | 37.50M | 28.57M |
| Interest Income | 0.00 | 575.00K | 126.00K | 143.00K | 393.00K | 192.00K |
| Interest Expense | 0.00 | 0.00 | 126.00K | 143.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 58.00K | 52.00K | 519.00K | 395.00K | 303.00K | 175.00K |
| EBITDA | -34.19M | -7.64M | -35.30M | -27.14M | -36.73M | -28.20M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -21.88M | -36.18M | -35.95M | -29.83M | -37.50M | -28.57M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -12.48M | 28.36M | 126.00K | 2.30M | 465.00K | 192.00K |
| Income Before Tax | -34.36M | -35.61M | -35.82M | -27.53M | -37.04M | -28.38M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -109.90K | 2.39M | -2.00M | -538.00K | -393.00K | 13.86K |
| Net Income | -34.36M | -35.61M | -35.82M | -27.53M | -37.04M | -28.38M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -7.65 | -23.20 | -23.66 | -58.24 | -35.85 | -33.10 |
| EPS Diluted | -7.65 | -23.20 | -23.66 | -58.24 | -35.85 | -33.10 |
| Weighted Avg Shares Out | 4.49M | 1.53M | 1.51M | 472.75K | 1.03M | 857.28K |
| Weighted Avg Shares Out (Dil) | 4.49M | 1.53M | 1.51M | 472.75K | 1.03M | 857.28K |
CalciMedica Announces Upcoming Presentations and Events in September
CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023
CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
Source: https://incomestatements.info
Category: Stock Reports